Prevalence of herpes simplex virus type 2 antibodies among pregnant women attending Federal Teaching Hospital, Ido-Ekiti, Nigeria

Oluboyo Bernard Oluwapelumi*, Fajuko Oluwadamilola Peace, Akele Richard Yomi, Akinseye Funmilayo Janet and Oluboyo Adeola Olanrewaju

Department of Medical Laboratory Science, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria.

Publication history: Received on 09 April 2020; revised on 14 April 2020; accepted on 24 April 2020

Article DOI: https://doi.org/10.30574/wjarr.2020.6.1.0093

Abstract
Herpes simplex virus type 2 (genital herpes) is mostly asymptomatic except if the immune system is compromised. However, infections could lead to preterm delivery, low infant birth weight, still birth, hydrops, cystic brain degeneration, and fetal growth retardation. Record of the prevalence of the viral infection is scanty among pregnant women in Ekiti State, Nigeria. This study was conducted to determine the prevalence of herpes simplex virus type 2 antibodies among pregnant women attending Federal Teaching Hospital Ido-Ekiti. Structured questionnaires were administered to obtain information such as age, incidence of miscarriages, marital status and number of pregnancies among the women who were examined. Ninety (90) pregnant women were examined for the presence of herpes simplex virus type 2 (HSV-2) IgG and IgM antibodies using enzyme linked immunosorbent assay (ELISA) technique. Prevalence of HSV-2 IgG and IgM antibodies among pregnant women was 64.4 % and 2.2 % respectively. A significant (p<0.05) number of the pregnant women recorded presence of IgG antibody to the virus. There was no statistical significant (p>0.05) difference between the prevalence of HSV-2 IgG antibody across age ranges, number of miscarriages, marital status and number of pregnancies. There may be need for antenatal screening of pregnant women for this virus in Ekiti State and perhaps generally in pregnancy to rule out the presence of genital herpes. With the risk of infection to fetus in mind, health policy makers may campaign against genital herpes to avert transmission of the virus to fetus before birth or after child birth.

Keywords: HSV-2; Pregnant women; Prevalence; Antibodies; HSV-2; Sexual behavior.

1. Introduction
Herpes simplex virus type 2 (HSV-2) is a universal, enveloped, and double stranded DNA virus, belonging to the family of Herpesviridae. It is the major cause of genital ulcers worldwide; causing principally anal and genital infections and may cause infections in other areas of the body [1]. HSV infection is contracted through direct contact with an active lesion or body fluid of an infected person. Clinical manifestations of HSV include: skin and mucosa infection, genital herpes, herpetic whitlow, herpes encephalitis, cognitive deficits of bipolar disorder and Alzheimer's disease [2]. Immunocompromised patients are said to have more severe disease [3].

Herpes simplex virus-2 (genital herpes) genital infection is one of the most common and relevant venereal diseases occurring in women. After local replication at the infection site, HSV-2 establishes a lifetime latent infection, with recurring genital lesions and eventual systemic spreading [4]. When compared with an uninfected control population, a significant increase of spontaneous abortions has been described in women with latent HSV-2 genital infections [5]. The virus may also be transmitted from mother to child during childbirth [6]. However, the risk of infection transmission is minimal if the mother has no symptoms or exposed blisters during delivery. The risk is greater when the mother is infected with the virus for the first time during late pregnancy [7].
Preterm delivery and low infant birth weight have been reported in women with HSV asymptomatic genital shedding [8]. Abnormal accumulation of fluid in body tissues or cavities, cystic brain degeneration and idiopathic fetal growth retardation were all reported to be related to HSV-2 genital infection [9]. After parturition, HSV-2 infection of neonates born to infected mothers is perhaps the most deleterious complication of the disease.

HSV-2 seroprevalence has been reported as 6% in the general population and 14% in pregnant women [10]. The prevalence of HSV infection is said to increase with age, with the highest around 40 years [11]. Furthermore, it has been reported that age, educational status, parity, stage of pregnancy and history of blood transfusion were not significantly associated with the viral prevalence [12].

This infection appears to be related to the number of sexual partners, and with respect to gender, infection is said to be more frequent in women than in men [13]. Moreover, ethnicity, poverty, cocaine abuse, earlier onset of sexual activity, sexual behaviour, and bacterial vaginosis are conditions capable of increasing a woman's possibility of infection before pregnancy [14]. Genital herpes during pregnancy has been linked with spontaneous abortion, intrauterine growth retardation, preterm labour, and congenital and neonatal herpes infections [15].

The major way of transmission of herpes simplex type 2 is through sexual intercourse. Herpes simplex for pregnant women can result in stillbirth. The long-term effect of herpes simplex type 2 infections is very severe especially in women. Knowledge of the prevalence of herpes simplex virus type 2 among pregnant women in Ekiti State will certainly help the health sector of the economy in policy making towards the control of the diseases among pregnant women. Records are however scanty on the prevalence of herpes simplex virus type 2 among pregnant women in Ekiti State. The aim of this study therefore is to determine the prevalence of herpes simplex virus type 2 antibodies among pregnant women in Ekiti State.

2. Material and methods

2.1. Study area

This study was conducted at Federal Teaching Hospital Ido-Ekiti, Ekiti State, among pregnant women attending antenatal clinic in the hospital. Patients come from different parts of the State to the Teaching Hospital for medical attention. The latitude of Ido-Ekiti is 7.843093 and the longitude is 5.182314 [Distanceto.com (2020). Find Coordinates.https://www.distanceto.com/coordinates/ng/ido-ekiti-latitude-longitude/history/75944.html last accessed 04 April, 2020]. Laboratory analysis was carried out in the Medical Laboratories of the Department of Medical Laboratory Science, Afe Babalola University, Ado-Ekiti (ABUAD), Ekiti State. Ado-Ekiti is a city in southwestern Nigeria and lies on latitude 7°35 and 7°38 north of the equator and longitude 5°10 and 5°15 east of the Greenwich Meridian [16]. Afe Babalola University is a private institution with its campus located at Km. 8.5, Afe Babalola way, opposite Federal Polytechnic, Ado-Ekiti.

2.2. Ethical Consideration

Ethical approval was sought for and obtained from the Federal Teaching Hospital, Ido-Ekiti, Ekiti State. The study participants were informed about the purpose of the study and written consent were obtained from each participant before sample collection.

2.3. Eligibility Criteria

Pregnant women attending FTH Ido-Ekiti, who consented to the study, were eligible for sampling. Non-pregnant women were excluded from the study.

2.4. Sample size

Ninety (90) pregnant women consented to the study and were enlisted.

2.5. Application of questionnaire

A semi-structured questionnaire was used to collect the demographic data of the participants, risk factors and birth history.
2.6. Sample collection

Five (5) ml of venous blood was collected from the cubital fossa of each of the consenting pregnant women using sterile needles, syringes and clean sample bottles. Serum was obtained by centrifuging each blood samples at 1000 rpm (revolution per minute) for 10 minutes. The sera were stored in the Medical Microbiology Laboratory of the Department of Medical Laboratory Science, ABUAD at -20°C until ready for assay [17].

2.7. Sample analysis

Analysis of the sample was carried out using HSV II IgG & IgM ELISA kit (MELSIN MEDICAL CO., LIMITED, China).

2.7.1. ELISA Assay principle [18].

Into the appropriate microliter plate wells pre-coated with the antigen, samples, positive control, and negative control are added and incubated. After incubation, it is washed to remove the uncombined enzyme, after which chromogen solution A and B is added changing the colour of the liquid to blue. At the effect of a weak acid, the colour becomes yellow. The colour change is measured spectrophotometrically at a wavelength of 450 nm. The presence or absence of IgG or IgM antibodies in the samples is determined by comparing the optical density (O.D) of the samples with the cut-off value.

2.7.2. Test procedure for IgG/IgM

The manufacturer’s procedure was strictly followed. The reagents provided were allowed to attain room temperature for 15 minute before use. The wash buffer was diluted with distilled water using ratio 1: 20 before use. The microtiter plate was set up with 1 well as blank, 2 wells as negative control and 2 wells as positive control. 100 µl of sample diluent was dispensed into the respective wells except the blank well, negative control well and positive control well. 100 µl of the negative and positive controls were dispensed into their wells respectively. 10 µl of samples was dispensed into their wells and the content was mixed by vibrating the plate gently.

The microplate was covered with a sealing paper and incubated in a microplate incubator (MARVOTECH PLATE INCUBATOR, China) at 37°C for 30 minutes [19]. After incubation, the microplate was washed five times using wash buffer. 100 µl of conjugate was added to each well except the blank; the microplate was covered with a sealing paper and also incubated in a microplate incubator at 37°C for 30 minutes. After incubation the microplate was washed five times with the diluted wash buffer in an automatic plate washer (MARVOTECH PLATE WASHER, China)[19]. 50 µl of substrate solution A and B was added to each well respectively and was mixed; the plate was covered and incubated at 37°C for 15 minutes. 50 µl of stop solution was added to each well and mixed. The absorbance was read in an ELIZA reader machine (MARVOTECH ELIZA READER, China) at wavelength of 450 nm [19].

2.7.3. Interpretation of result IgG/IgM

If the mean negative control O.D ≤ 0.1 and the mean positive control O.D ≥ 0.8, the test is valid.

Cut-off O.D = the mean O.D value of the negative control × 2.1

Positive results: Sample O.D ≥ cut-off O.D

Negative results: Sample O.D < cut-off O.D

2.8. Statistical analysis

Collected data were analyzed using statistical package for social science (SPSS) version 17. Chi square was used to compare age, miscarriage/stillbirth, number of pregnancies with prevalence of herpes simplex virus type 2 at 0.05 level of significance.

3. Results

The total prevalence of HSV-2 IgG was 58 (64.4 %). This was significantly higher (p<0.05) than the number of pregnant women that tested negative to HSV-2 IgG antibodies. The numbers of pregnant women that tested positive to HSV-2 IgM were 2 (2.2 %). This was not statistically significant (p>0.05). The two (2) positive IgM women were among those 58 women that tested positive to IgG.

Table 1 shows the prevalence of HSV-2 IgG and IgM antibodies across the age ranges of the pregnant women. The prevalence of IgG antibody was not significant (p>0.05) across the age ranges of the pregnant women. However, prevalence was highest at age range 20-24 (75 %) and lowest at age range 25-29 (60 %). Only two pregnant women were positive to HSV 2 IgM antibody and they occurred at age range 30-34 (6 %).
The prevalence of HSV-2 IgG antibody among women who have had past history of miscarriages was not significant (p>0.05) in relation to women who had no miscarriages in the past (Table 2).

The percentage of pregnant unmarried women (single) that tested positive to HSV-2 IgG (76.9 %) was not significantly higher (p>0.05) in relation to that of pregnant married women (62.3 %) (Table 2). Prevalence of HSV-2 IgG antibodies among pregnant women in relation to number of pregnancies is shown in Table 2. The prevalence of HSV-2 antibody among women that have had multiple pregnancies is not significant (p>0.05) in relation to women who are just getting pregnant for the first time.

**Table 1**: Prevalence of HSV-2 IgG and IgM antibodies across the age ranges of pregnant women

<table>
<thead>
<tr>
<th>Age ranges</th>
<th>Total</th>
<th>IgG Antibodies</th>
<th>( \chi^2 )</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>90</td>
<td>58</td>
<td>11.574</td>
<td>0.868</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Positive (%)</td>
<td>Negative (%)</td>
<td></td>
</tr>
<tr>
<td>20-24</td>
<td>8</td>
<td>6</td>
<td>2</td>
<td>75</td>
</tr>
<tr>
<td>25-29</td>
<td>30</td>
<td>18</td>
<td>12</td>
<td>60</td>
</tr>
<tr>
<td>30-34</td>
<td>33</td>
<td>21</td>
<td>12</td>
<td>64</td>
</tr>
<tr>
<td>35-39</td>
<td>16</td>
<td>11</td>
<td>5</td>
<td>69</td>
</tr>
<tr>
<td>40-44</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>67</td>
</tr>
</tbody>
</table>

**IgM Antibodies**

<table>
<thead>
<tr>
<th>Age ranges</th>
<th>Total</th>
<th>IgM Antibodies</th>
<th>( \chi^2 )</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>90</td>
<td>2</td>
<td>14.690</td>
<td>0.683</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Positive (%)</td>
<td>Negative (%)</td>
<td></td>
</tr>
<tr>
<td>20-24</td>
<td>8</td>
<td>0</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>25-29</td>
<td>30</td>
<td>0</td>
<td>30</td>
<td>0</td>
</tr>
<tr>
<td>30-34</td>
<td>33</td>
<td>2</td>
<td>31</td>
<td>6</td>
</tr>
<tr>
<td>35-39</td>
<td>16</td>
<td>0</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>40-44</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

p>0.05, Not significant.

**Table 2**: Prevalence of HSV-2 IgG antibodies among pregnant women in relation to miscarriages, marital status and number of pregnancies

<table>
<thead>
<tr>
<th>Parameters</th>
<th>IgG antibodies</th>
<th>( \chi^2 )</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Miscarriage status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miscarriage</td>
<td>15</td>
<td>7 (46.7)</td>
<td>8 (53.3)</td>
</tr>
<tr>
<td>No miscarriage</td>
<td>75</td>
<td>51 (68.0)</td>
<td>24 (32.0)</td>
</tr>
<tr>
<td><strong>Marital status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>77</td>
<td>48 (62.3)</td>
<td>29 (37.7)</td>
</tr>
<tr>
<td>Single</td>
<td>13</td>
<td>10 (76.9)</td>
<td>3 (23.1)</td>
</tr>
<tr>
<td><strong>No. of pregnancies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple</td>
<td>44</td>
<td>29 (65.9)</td>
<td>15 (34.1)</td>
</tr>
<tr>
<td>Single</td>
<td>46</td>
<td>29 (63.0)</td>
<td>17 (37.0)</td>
</tr>
</tbody>
</table>

p>0.05, Not significant.
4. Discussion

An overall prevalence rate of 64.4 % was recorded for HSV-2 IgG and 2.2 % was recorded for HSV-2 IgM. The percentage of pregnant women having recent infection (presence of IgM) in the present study was low among those who tested positive to genital herpes IgG. The seroprevalence of the IgG is relatively high when they are compared with similar studies carried out in other States in Nigeria. There has been a report of 35.5 % seroprevalence in a tertiary health facility in central Nigeria [12]. Also record of 46.3 % seroprevalence among pregnant women in Benin, Nigeria [20] has been documented.

Findings in the present study was lower than 96.5 % reported among pregnant women in urban health training Yopougon-Attie (Cote D’ivoire) [21] but higher than 63.1 % seroprevalence recorded among pregnant women in turkey [22] and 7.6-8.4 % recorded in Italy [23]. Thus, seroprevalence vary from place to place. The finding in this study is comparable with the report obtained in Turkey but quite lower than is reported in Cote D’ivoire. The reason for the variation might be related to the rate of exposure to the virus, the prevalence of the virus in a particular locality, the rate of susceptibility to the virus and the immune status of individuals.

There was no statistically significant difference in infection across the ages of pregnant women. The records that genital herpes increase with age [11] did not appear supported by the present study. Infection can occur at any age if exposed to the virus. This is also supported by Oti and colleagues [12]. However, age range of 20-24 recorded the highest prevalence (75 %, Table 1) in the present study. This is in accordance with the work done at central Nigeria [12] and also with the work which was carried out in Port Harcourt, Nigeria [24]. This age group also coincided with the ages of marriageable ladies that are not yet married but were involved in premarital vaginal sex. Higher prevalence rate was recorded among such group than among married women (Table 2). The difference is however not statistically significant (p>0.05).

Also the prevalence of HSV 2 IgG antibody among women who have had miscarriages was not significant (p>0.05) in relation to women who have had no miscarriages in the past. This report is in accord with other researcher’s finding [25] but contradicted by the findings of Marquez and other researchers [26] who reported correlation between herpes simplex virus type 2 infection and miscarriages.

Although higher prevalence of HSV-2 antibodies were recorded among unmarried (single) pregnant women, the difference was not significant (p>0.05). Record on prevalence of the virus in relation to single and married women are scanty. From this study it implied that both married and unmarried women are equally susceptible to HSV 2 infection. However, Kalu et al. [20] recorded statistically significant difference between the prevalence of HSV-2 infection among the married women and their unmarried counterparts.

The prevalence of HSV-2 antibody among women that have had multiple pregnancies was not significant (p>0.05) in relation to women who are just getting pregnant for the first time in the present study. This is consistent with past records [12].

5. Conclusion

Prevalence of 64.4 % HSV type 2 IgG antibodies was recorded in this study among pregnant women in Ekiti State. A total of 2.2 % of the examined pregnant women recorded recent infection (Presence of IgM). Prevalence was found not to be significant in relation to ages of the women, marital status, number of children (pregnancies), and past miscarriages. This study has provided information on the burden of HSV-2 infection among pregnant women attending Federal Teaching Hospital, Ido-Ekiti, Ekiti State, Nigeria.

Compliance with ethical standards

Acknowledgments

The cooperation of fellow Medical Laboratory Scientists in the Medical Microbiology Unit of the Department of Medical Laboratory Science in the storage of samples is appreciated.

Disclosure of conflict of interest

All authors declare no form of conflict of interest in this study.
Statement of ethical approval

Ethical approval was sought for and obtained from the Federal Teaching Hospital, Ido-Ekiti, Ekiti State. The study participants were informed about the purpose of the study and written consent were obtained from each participant before sample collection. Regarding human subject researches, the procedures are in line with Helsinki Declaration of 1975, as revise in 2000; only blood samples were required from the consented participants.

Statement of informed consent

Informed consent was obtained from all individual participants included in the study.

References


How to cite this article